Medical News

Patients Exposed to Dabigatran have a Low Risk of MI

Patients exposed to dabigatran have a low risk of myocardial infarction (MI), confirmed a recent meta-analysis that provided a pooled data of over...

24 Sep, 2018

 
Email this page
Early rather than Late Prasugrel Pre-treatment Reduces in-stent Thrombosis after PCI in ACS Patients

A recent study demonstrated that early (at the time of diagnosis of acute coronary syndrome ) rather than late (after the coronary angiography prior...

24 Sep, 2018

 
Email this page
Guideline-directed Heart Failure Pharmacotherapy, Underutilised in Asian HFrEF Patients

A recent prospective multinational study from Asia reported the prescribing patterns of guideline-directed medical therapies and analysis of its...

19 Sep, 2018

 
Email this page
Predictors of LVEF Improvement in Ischemic HFrEF Patients following Revascularization -The Real-World Data

One of the first real-world studies has identified various predictors for the improvement in left ventricular ejection fraction (LVEF) following...

19 Sep, 2018

 
Email this page

Key Trials

Sacubitril/Valsartan Improves Physical and Social Activity Limitations in HFrEF Patients

Treatment with sacubitril/valsartan improves physical and social limitations in HFrEF patients in addition to the CV benefits that it provides.

Sacubitril/Valsartan vs. Enalapril in HFrEF Patients: Analyzing the Renal Impact and Associated Outcomes

The study analyzes renal effects and the associated outcomes of sacubitril/valsartan vs. enalapril in HF patients with reduced ejection fraction.  

Treatment with Macitentan Reduces Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension – SERAPHIN Study

Results of the SERAPHIN study demonstrated that treatment with macitentan resulted in significant reduction in morbidity and mortality in patients...

Initiation/Uptitration of Sacubitril/Valsartan in HFrEF Patients: Insights from the TITRATION Trial

The TITRATION trial assessed tolerability of initiating/uptitrating sacubitril/valsartan using a conservative or condensed regimen in HFrEF patients...

Slide Library

Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH

Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...

 
Email this page
Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...

 
Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

 
Email this page
Ambrisentan in PAH

Ambrisentan is a propanoic acid, non-sulfonamide, selective endothelin type A (ETA) receptor antagonist which is used in pulmonary arterial...

 
Email this page

Our Publications

Azmarda (Sacubitril/Valsartan) FAQs

This booklet on frequently asked questions on sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) provides...

Retefast (Reteplase) Datasheet

This datasheet provides an overview on the pharmacology, clinical efficacy, safety, indications and dosage of reteplase.

Pulmonary Hypertension – An Update

This article summarises the definition, classification, pathogenesis, assessment, prognosis, diagnosis and treatment for PH.

The Changing Landscape of CV Risk Reduction - Is LDL Lowering Sufficient: Questions & Answers (Dr. Michael Miller, USA)

Here is a set of questions addressed by Dr. Michael Miller, a renowned cardiologist and lipidologist during the “PROMISE” meet held in India.

Patient Education

Understanding Angioplasty

Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.

Managing Your Angina

It explains the causes, risk factors, symptoms and treatment options for angina, as well as the various do’s and don’t’s in a patient-friendly...

Understanding Obesity

This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss. 

Hypertension

Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure. 

Poll

What percent of your patients who need oral anticoagulation, receive warfarin?
<20%
18% (2 votes)
20-40%
18% (2 votes)
40-50%
9% (1 vote)
50-70%
9% (1 vote)
70-80%
36% (4 votes)
Almost all
9% (1 vote)
Total votes: 11